Phase 3 Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand the trial and have agreed in writing to take part
- People who have been diagnosed with atrial fibrillation (an irregular heartbeat) or atrial flutter, confirmed by a heart tracing (ECG) or monitor recording
- People aged 65–74 with a stroke risk score of 4 or higher, or aged 75 and over with a stroke risk score of 3 or higher, based on a specific medical scoring system called CHA2DS2VASc (confirm with trial site)
- People whose doctor has decided — before and separately from this study — that blood-thinning tablets are not suitable for them because the risks are greater than the benefits, or who are unwilling to take them
- People who have at least one factor that increases their bleeding risk, such as severe kidney problems, planned daily use of blood-thinning pain medicines, a history of bleeding in a dangerous area of the body, regular use of anti-inflammatory pain medicines (such as ibuprofen), frailty, or a history of frequent falls
- People whose doctor has decided — before and separately from this study — that a surgical device to close off a part of the heart (called the left atrial appendage) is not suitable for them, is not available, or who are unwilling to have the procedure
Who may not be able to join:
- People whose irregular heartbeat is caused by a short-term, reversible condition, such as recent heart surgery, a blood clot in the lungs, untreated thyroid problems, or alcohol use
- People who have taken certain blood-thinning medicines (such as warfarin or newer anticoagulants like apixaban or rivaroxaban) within the 60 days before joining, or who were newly diagnosed with atrial fibrillation within that same period
- People who have had a bleed inside the brain or eye in the 3 months before screening, or who have ever had a spontaneous bleed inside the brain without being on blood-thinning treatment
- People who have had a stroke in the 14 days before joining, or a mini-stroke (TIA) in the 3 days before joining
- People who have a mechanical heart valve, or who have a valve condition that is expected to need a mechanical valve procedure during the trial
- People who are on kidney dialysis at the time of screening, or who are expected to start dialysis within 6 months
- Other criteria set out in the study protocol may also apply (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-888-669-6682
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Efficacy: Time to first event of ischemic stroke or systemic embolism (SE); Safety: Time to first occurrence of Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.